Compare Quest Diagnostics Inc (DGX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs T Rowe Price Group Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while T Rowe Price Group Inc trades at $105.6 (market cap $22.23B). The key difference: Quest Diagnostics Inc and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and T Rowe Price Group Inc for 115 Days on average.
| DGX | TROW | |
|---|---|---|
Market Cap | $25.48B | $22.23B |
Volume | 941,866 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $247.45 | $121.68 |
52-Week Low | $173.49 | $86.19 |
Typical Hold Time | 56 Days | 115 Days |
Enterprise Value | $31.23B | $19.43B |
Dividend Yield | 1.49% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
T. Rowe Price (TROW) trades at $105.16, up 1.05% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $7.31B revenue, 29.26% net margin, and attractive valuation at 10.46 P/E. Recent earnings show two beats out of three quarters, while assets under management reached $1.90T in August 2026 despite net outflows.
TROW presents a compelling value opportunity with solid dividend growth and reasonable valuation, though technical weakness and analyst caution warrant attention. The stock's 40-year dividend growth history and expanding ETF offerings through F/m Investments acquisition provide stability, while market volatility and fee pressure remain key risks for the asset management business.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
